Aarti Drugs share price, P/E, ROE & financials

Aarti Drugs (AARTIDRUGS) had a P/E of 21.3× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 16% below their 52-week high. Its ROCE of 13% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales fell 2.3% a year over 3 years while net profit grew 5.4%. Its dividend yield is 0.5%, and debt is 0.37× equity. It is a small-cap company with a market cap of ₹4,077 Cr, ranked 48th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 12% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹445.15
Day high: ₹454.80
Day low: ₹435.10
Prev. close: ₹445.15
Volume: 3.7 L

Health check

3 good · 1 fair · 2 to check

ReturnsBehind
−11.6% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 21.3 vs industry 28.7.
GrowthSlow
Sales −2.3%, profit +5.4% a year over 3 years.
ProfitabilityAverage
ROCE 12.9% vs peer median 17.9%.
Balance sheetSolid
Debt 0.37× equity, interest covered 7.3×, Piotroski 6 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹4,077 Cr, #48 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹2,854 Cr · profit ₹229 Cr

Market cap: ₹4,077 Cr; Small cap
P/E: 21.3; Industry 28.7
Price to book: 2.43; Peers 4.99
Dividend yield: 0.45%
ROE: 14.5%; Peers 14.7%
ROCE: 12.9%; Peers 17.9%
Debt to equity: 0.37; Debt ₹620 Cr
EPS (TTM): ₹20.93; Face value ₹10
OPM (TTM): 12.4%; Net margin 8.0%
Sales growth: +19.0%; Latest quarter vs a year ago
Profit growth: −6.9%; Latest quarter vs a year ago
Price to sales: 1.43; EV/EBITDA 12.2

Strengths

Quarterly sales up 19.0% on a year ago.
P/E of 21.3 against an industry P/E of 28.7.
Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Aarti Drugs

Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin…

Headquarters: Mumbai
Employees: 1,355
Sector: Healthcare
ISIN: INE767A01016
Website: aartidrugs.co.in

Price range

52 weeks

₹318.95₹534.00

Today

₹435.10₹454.80

Avg volume (3M): 4.6 L
1-year return: minus 11.6%
From 52-week high: minus 16.3%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
AARTIDRUGSAarti Drugs	446.75	plus 0.36%	4,077	21.3	2.43	12.9%	14.5%	12.4%	−2.3%	5.4%	0.45%	minus 11.6%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
591	653	602	720	703
516	569	547	625	605
74.1	84.3	55	95.8	98.2
12.5%	12.9%	9.1%	13.3%	14.0%
0.3	0.1	1.2	0.8	0.8
8.6	7.7	9.3	8.2	9.2
14.7	16.3	18	18	18.5
–	–	–	–	−2.1
51.1	60.4	29	70.4	69.2
−5.6%	25.2%	−39.7%	21.5%	27.6%
53.9	45.3	40.5	55.2	50.2
5.91	4.95	4.44	6.05	5.49

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −2.3%
Profit CAGR 3Y: +5.4%
EPS CAGR 3Y: +5.9%
ROE: 14.5%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
2,706	2,509	2,369	2,521
–	minus 7.3%	minus 5.6%	+6.4%
2,389	2,180	2,070	2,201
317	329	299	320
11.7%	13.1%	12.6%	12.7%
−7.3	−6.3	8.2	−4.9
33.3	33.5	35.9	33.7
50.3	51.4	55.8	67
−1.5	−2.4	−3.7	−3.7
224	236	212	211
25.8%	27.1%	20.6%	7.6%
166	171	168	195
–	+3.1%	minus 1.9%	+15.9%
17.97	18.56	18.35	21.36

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
92.6	91.9	91.3	91.3
1,100	1,190	1,278	1,458
609	564	615	577
620	587	591	690
2,421	2,432	2,575	2,815
886	1,054	1,150	1,211
210	244	291	141
18.8	20	22.4	27.3
8.4	8.9	7	8.2
1,298	1,105	1,104	1,428
2,421	2,432	2,575	2,815

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
133	359	245	254
−164	−224	−165	−173
16.5	−136	−82.1	−77.4
−14.1	−0.8	−2.2	2.7
−165	−226	−177	−173
−31.5	133	67.4	80.2
−9.4	−9.3	−9.1	−18.2

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 10.9% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you